Trials / Completed
CompletedNCT04009941
Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
Study on the Efficacy and Safety of 4.5mg Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Peking University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single-center, single-arm clinical study, to evaluate the clinical efficacy, safety and tolerance of patients with early breast cancer receiving ddEC adjuvant chemotherapy, accepting PEG-rhG-CSF as primary prevention of neutropenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PEG-rhG-CSF | 4.5mg per cycle, 24 hours after chemotherapy |
Timeline
- Start date
- 2019-08-01
- Primary completion
- 2020-01-18
- Completion
- 2020-01-31
- First posted
- 2019-07-08
- Last updated
- 2020-10-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04009941. Inclusion in this directory is not an endorsement.